PMID: 9187443Jan 1, 1997Paper

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie

Annals of Oncology : Official Journal of the European Society for Medical Oncology
John M M RaemaekersE Noordijk

Abstract

Failure to reach complete remission (CR) with chemotherapy in advanced stages of Hodgkin's disease is considered a poor prognostic factor for progression-free and overall survival. The role of radiotherapy after chemotherapy-induced remission is controversial. In 1989, the EORTC/GPMC started a randomized phase III trial on involved-field RT (IF-RT) after MOPP/ABV hybrid-induced remission in patients with stage III/IV Hodgkin's disease. In this ongoing trial, patients in CR after chemotherapy are randomized between IF-RT and no further treatment. Patients in partial remission (PR) all receive IF-RT. Patients, age 15-70 years, with previously untreated stage III/IV Hodgkin's disease are eligible. The randomized treatment arms are still blinded. The interim analysis of May 1996 focuses on the outcome of patients in chemotherapy-induced PR. A total of 405 of 493 registered patients were evaluable for response to chemotherapy. Fifty-nine percent of patients attained a CR, 37% a PR, and only 4% failed to respond. The IF-RT was actually given to 90% of the PR patients. After a median follow-up of 43 months, the five year progression-free and overall survival for patients in PR was 75% and 87%, respectively. IF-RT after MOPP/ABV-induce...Continue Reading

Citations

Mar 17, 2004·Cancer Treatment Reviews·Tejpal Gupta, Siddhartha Laskar
Jun 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Magdalena DyduchAndrzej Sokolowski
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·R M'kacherP Carde
Feb 23, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J RaemaekersP Carde
Jun 23, 2000·Critical Reviews in Oncology/hematology·H EghbaliP Richaud
May 2, 2003·European Journal of Nuclear Medicine and Molecular Imaging·K E Kogel, J W Sweetenham
Apr 11, 2001·Current Oncology Reports·A Josting, V Diehl
Oct 7, 2004·International Journal of Radiation Oncology, Biology, Physics·Ferah YildizGülten Tekuzman
Nov 26, 2008·International Journal of Radiation Oncology, Biology, Physics·Mohamed A Alm El-DinAlphonse G Taghian
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Volker Diehl
Jul 13, 2005·European Journal of Haematology. Supplementum·Houchingue EghbaliUNKNOWN EORTC Lymphoma Group
Oct 20, 2005·The Cochrane Database of Systematic Reviews·J G FranklinL Specht
Aug 6, 2008·Nature Clinical Practice. Oncology·Andrew M EvensVolker Diehl
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Berthe M P AlemanFlora E van Leeuwen
Nov 28, 2001·Hematology·J M ConnorsS J Horning
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
R I Fisher
Annals of Oncology : Official Journal of the European Society for Medical Oncology
P M Mauch
Annals of Oncology : Official Journal of the European Society for Medical Oncology
Volker DiehlMarkus Loeffler
Annals of Oncology : Official Journal of the European Society for Medical Oncology
George P Canellos
© 2021 Meta ULC. All rights reserved